$VCEL
Vericel Corp

2016 Q3 Form 10-Q Financial Statement

#000162828016018710 Filed on August 08, 2016

View on sec.gov

Income Statement

Concept 2016 Q3 2016 Q2 2015 Q2
Revenue $10.93M $12.82M $13.59M
YoY Change -3.36% -5.64% 206.63%
Cost Of Revenue $6.856M $7.300M $6.901M
YoY Change 1.24% 5.78% 37.77%
Gross Profit $4.073M $5.523M $6.689M
YoY Change -10.23% -17.43% -1259.27%
Gross Profit Margin 37.27% 43.07% 49.22%
Selling, General & Admin $7.010M $6.449M $5.585M
YoY Change 23.55% 15.47% 55.96%
% of Gross Profit 172.11% 116.77% 83.5%
Research & Development $3.443M $4.058M $3.369M
YoY Change -7.94% 20.45% -22.8%
% of Gross Profit 84.53% 73.47% 50.37%
Depreciation & Amortization $470.0K $470.0K $200.0K
YoY Change 17.5% 135.0% 100.0%
% of Gross Profit 11.54% 8.51% 2.99%
Operating Expenses $10.45M $10.51M $8.954M
YoY Change 11.04% 17.34% 12.7%
Operating Profit -$6.380M -$4.984M -$2.265M
YoY Change 30.82% 120.04% -73.42%
Interest Expense $86.00K $3.000K $2.000K
YoY Change 4200.0% 50.0% 0.0%
% of Operating Profit
Other Income/Expense, Net -$295.0K $1.940M $113.0K
YoY Change -163.99% 1616.81% -97.09%
Pretax Income -$6.680M -$3.040M -$2.150M
YoY Change 51.13% 41.4% -53.66%
Income Tax
% Of Pretax Income
Net Earnings -$6.675M -$3.044M -$2.152M
YoY Change 51.15% 41.45% -53.6%
Net Earnings / Revenue -61.08% -23.74% -15.84%
Basic Earnings Per Share
Diluted Earnings Per Share -$293.8K -$134.0K -$90.37K
COMMON SHARES
Basic Shares Outstanding 24.00M shares 23.93M shares 23.79M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2016 Q3 2016 Q2 2015 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $8.900M $9.800M $20.20M
YoY Change -52.41% -51.49% 176.71%
Cash & Equivalents $8.900M $9.800M $20.20M
Short-Term Investments
Other Short-Term Assets $741.0K $1.046M $2.270M
YoY Change 44.16% -53.92% 272.13%
Inventory $3.607M $2.393M $2.078M
Prepaid Expenses
Receivables $7.871M $9.031M $8.980M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $21.10M $22.31M $33.55M
YoY Change -26.01% -33.51% 137.71%
LONG-TERM ASSETS
Property, Plant & Equipment $4.215M $4.351M $4.616M
YoY Change -2.32% -5.74% 93.38%
Goodwill
YoY Change
Intangibles $2.708M $2.778M $3.057M
YoY Change -9.34% -9.13% -8.39%
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $6.923M $7.129M $7.673M
YoY Change -5.19% -7.09% 34.05%
TOTAL ASSETS
Total Short-Term Assets $21.10M $22.31M $33.55M
Total Long-Term Assets $6.923M $7.129M $7.673M
Total Assets $28.02M $29.43M $41.22M
YoY Change -21.77% -28.59% 107.8%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.467M $5.305M $6.120M
YoY Change 9.45% -13.32% 110.38%
Accrued Expenses $24.00K $82.00K $140.0K
YoY Change -71.76% -41.43% -94.41%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $15.36M $11.46M $10.82M
YoY Change 65.86% 5.89% -36.56%
LONG-TERM LIABILITIES
Long-Term Debt $42.00K $52.00K $91.00K
YoY Change -48.15% -42.86%
Other Long-Term Liabilities $1.200M $800.0K $66.00K
YoY Change 1718.18% 1112.12%
Total Long-Term Liabilities $42.00K $52.00K $157.0K
YoY Change -71.43% -66.88%
TOTAL LIABILITIES
Total Short-Term Liabilities $15.36M $11.46M $10.82M
Total Long-Term Liabilities $42.00K $52.00K $157.0K
Total Liabilities $16.63M $12.33M $10.98M
YoY Change 76.75% 12.32% -35.82%
SHAREHOLDERS EQUITY
Retained Earnings -$337.4M -$330.7M
YoY Change
Common Stock $310.2M $309.4M $306.6M
YoY Change 0.98% 0.92%
Preferred Stock
YoY Change
Treasury Stock (at cost) $3.150M $3.150M
YoY Change
Treasury Stock Shares
Shareholders Equity $11.39M $17.11M $30.24M
YoY Change
Total Liabilities & Shareholders Equity $28.02M $29.43M $41.22M
YoY Change -21.77% -28.59% 107.8%

Cashflow Statement

Concept 2016 Q3 2016 Q2 2015 Q2
OPERATING ACTIVITIES
Net Income -$6.675M -$3.044M -$2.152M
YoY Change 51.15% 41.45% -53.6%
Depreciation, Depletion And Amortization $470.0K $470.0K $200.0K
YoY Change 17.5% 135.0% 100.0%
Cash From Operating Activities -$4.180M -$5.130M -$4.480M
YoY Change 480.56% 14.51% -26.19%
INVESTING ACTIVITIES
Capital Expenditures -$240.0K -$1.060M -$1.210M
YoY Change -68.83% -12.4% 12000.0%
Acquisitions
YoY Change
Other Investing Activities -$90.00K $0.00 $0.00
YoY Change -100.0%
Cash From Investing Activities -$330.0K -$1.060M -$1.200M
YoY Change -57.69% -11.67% -215.38%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 3.560M 2.490M 0.000
YoY Change -35700.0% -100.0%
NET CHANGE
Cash From Operating Activities -4.180M -5.130M -4.480M
Cash From Investing Activities -330.0K -1.060M -1.200M
Cash From Financing Activities 3.560M 2.490M 0.000
Net Change In Cash -950.0K -3.700M -5.680M
YoY Change -37.09% -34.86% 261.78%
FREE CASH FLOW
Cash From Operating Activities -$4.180M -$5.130M -$4.480M
Capital Expenditures -$240.0K -$1.060M -$1.210M
Free Cash Flow -$3.940M -$4.070M -$3.270M
YoY Change -7980.0% 24.46% -46.04%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
-93000 USD
us-gaap Payments For Proceeds From Tenant Allowance
PaymentsForProceedsFromTenantAllowance
0 USD
us-gaap Payments For Proceeds From Tenant Allowance
PaymentsForProceedsFromTenantAllowance
-607000 USD
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
0 USD
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
96000 USD
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
1555000 USD
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
1074000 USD
us-gaap Preferred Stock Accretion Of Redemption Discount
PreferredStockAccretionOfRedemptionDiscount
700000 USD
us-gaap Preferred Stock Accretion Of Redemption Discount
PreferredStockAccretionOfRedemptionDiscount
11000 USD
CY2016Q2 astm Common Stock Remaining Capacity
CommonStockRemainingCapacity
7800000 USD
CY2011Q3 astm Common Stock Value Registeredon Form S3
CommonStockValueRegisteredonFormS3
100000000 USD
astm Convertible Preferred Stock Conversion Period
ConvertiblePreferredStockConversionPeriod
P5Y
CY2015Q4 astm Convertible Preferred Stock Maximum Beneficial Ownership Percentage
ConvertiblePreferredStockMaximumBeneficialOwnershipPercentage
0.0999
CY2015Q4 astm Convertible Preferred Stock Maximum Beneficial Ownership Percentage Upon Holders Election
ConvertiblePreferredStockMaximumBeneficialOwnershipPercentageUponHoldersElection
0.1499
CY2015Q2 astm Depreciation Depletionand Amortization Excluding Intangible Assets
DepreciationDepletionandAmortizationExcludingIntangibleAssets
200000 USD
astm Depreciation Depletionand Amortization Excluding Intangible Assets
DepreciationDepletionandAmortizationExcludingIntangibleAssets
500000 USD
CY2016Q2 astm Depreciation Depletionand Amortization Excluding Intangible Assets
DepreciationDepletionandAmortizationExcludingIntangibleAssets
400000 USD
astm Depreciation Depletionand Amortization Excluding Intangible Assets
DepreciationDepletionandAmortizationExcludingIntangibleAssets
800000 USD
CY2015Q4 astm Lineof Credit Current Netof Deferred Costs
LineofCreditCurrentNetofDeferredCosts
0 USD
CY2016Q2 astm Lineof Credit Current Netof Deferred Costs
LineofCreditCurrentNetofDeferredCosts
2304000 USD
CY2016Q2 astm Operatingand Capital Leasesand Purchase Commitments Future Minimum Payments Due
OperatingandCapitalLeasesandPurchaseCommitmentsFutureMinimumPaymentsDue
26085000 USD
CY2015Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
0 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
0 USD
CY2016Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
0 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-10000 USD
CY2016Q2 astm Operatingand Capital Leasesand Purchase Commitments Future Minimum Payments Due Current
OperatingandCapitalLeasesandPurchaseCommitmentsFutureMinimumPaymentsDueCurrent
2595000 USD
CY2016Q2 astm Operatingand Capital Leasesand Purchase Commitments Future Minimum Payments Due In Four Years
OperatingandCapitalLeasesandPurchaseCommitmentsFutureMinimumPaymentsDueInFourYears
4267000 USD
CY2016Q2 astm Operatingand Capital Leasesand Purchase Commitments Future Minimum Payments Due In Three Years
OperatingandCapitalLeasesandPurchaseCommitmentsFutureMinimumPaymentsDueInThreeYears
4622000 USD
CY2016Q2 astm Operatingand Capital Leasesand Purchase Commitments Future Minimum Payments Due In Two Years
OperatingandCapitalLeasesandPurchaseCommitmentsFutureMinimumPaymentsDueInTwoYears
4940000 USD
CY2016Q2 astm Operatingand Capital Leasesand Purchase Commitments Future Minimum Payments Due Thereafter
OperatingandCapitalLeasesandPurchaseCommitmentsFutureMinimumPaymentsDueThereafter
5275000 USD
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2016
dei Document Period End Date
DocumentPeriodEndDate
2016-06-30
dei Document Type
DocumentType
10-Q
dei Entity Central Index Key
EntityCentralIndexKey
0000887359
CY2016Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
23995116 shares
dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
dei Entity Registrant Name
EntityRegistrantName
Vericel Corp
CY2015Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
3603000 USD
CY2016Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
2892000 USD
CY2015Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
7588000 USD
CY2016Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
5305000 USD
CY2015Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
10919000 USD
CY2016Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
9031000 USD
CY2015Q4 us-gaap Accrued Bonuses Current And Noncurrent
AccruedBonusesCurrentAndNoncurrent
1956000 USD
CY2016Q2 us-gaap Accrued Bonuses Current And Noncurrent
AccruedBonusesCurrentAndNoncurrent
1325000 USD
CY2015Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
306000 USD
CY2016Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
82000 USD
CY2015Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
5638000 USD
CY2016Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
6326000 USD
CY2015Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
40000 USD
CY2016Q2 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
86000 USD
CY2016Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
100000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
200000 USD
CY2015Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4300000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6400000 shares
CY2015Q4 us-gaap Assets
Assets
34309000 USD
CY2016Q2 us-gaap Assets
Assets
29434000 USD
CY2015Q4 us-gaap Assets Current
AssetsCurrent
27343000 USD
CY2016Q2 us-gaap Assets Current
AssetsCurrent
22305000 USD
us-gaap Business Combination Bargain Purchase Gain Recognized Amount
BusinessCombinationBargainPurchaseGainRecognizedAmount
0 USD
us-gaap Business Combination Bargain Purchase Gain Recognized Amount
BusinessCombinationBargainPurchaseGainRecognizedAmount
-86000 USD
CY2016Q2 us-gaap Capital Lease Obligations
CapitalLeaseObligations
97000 USD
CY2016Q2 us-gaap Capital Leases Future Minimum Payments Due Current
CapitalLeasesFutureMinimumPaymentsDueCurrent
22000 USD
CY2016Q2 us-gaap Capital Leases Future Minimum Payments Due In Five Years
CapitalLeasesFutureMinimumPaymentsDueInFiveYears
0 USD
CY2016Q2 us-gaap Capital Leases Future Minimum Payments Due In Four Years
CapitalLeasesFutureMinimumPaymentsDueInFourYears
0 USD
CY2016Q2 us-gaap Capital Leases Future Minimum Payments Due In Three Years
CapitalLeasesFutureMinimumPaymentsDueInThreeYears
32000 USD
CY2016Q2 us-gaap Capital Leases Future Minimum Payments Due In Two And Three Years
CapitalLeasesFutureMinimumPaymentsDueInTwoAndThreeYears
43000 USD
CY2014Q4 us-gaap Cash
Cash
30343000 USD
CY2015Q2 us-gaap Cash
Cash
20218000 USD
CY2015Q4 us-gaap Cash
Cash
14581000 USD
CY2016Q2 us-gaap Cash
Cash
9835000 USD
CY2015Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2016Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2015Q4 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2016Q2 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2015Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2016Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2015Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
23786000 shares
CY2016Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
23891000 shares
CY2015Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
23786000 shares
CY2016Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
23786000 shares
CY2015Q4 us-gaap Common Stock Value
CommonStockValue
307766000 USD
CY2016Q2 us-gaap Common Stock Value
CommonStockValue
309437000 USD
CY2015Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2152000 USD
CY2016Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3044000 USD
CY2015Q2 us-gaap Cost Of Goods Sold
CostOfGoodsSold
6901000 USD
us-gaap Cost Of Goods Sold
CostOfGoodsSold
12469000 USD
CY2016Q2 us-gaap Cost Of Goods Sold
CostOfGoodsSold
7300000 USD
us-gaap Cost Of Goods Sold
CostOfGoodsSold
13860000 USD
CY2015Q4 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
0 USD
CY2016Q2 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
96000 USD
CY2016Q2 us-gaap Deferred Rent Credit
DeferredRentCredit
900000 USD
CY2015Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
118000 USD
CY2016Q2 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
460000 USD
CY2015Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
0 USD
CY2016Q2 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
820000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
672000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
923000 USD
CY2015Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.16
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.43
CY2016Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.22
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.46
CY2015Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1341000 USD
CY2016Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1485000 USD
CY2015Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-112000 USD
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
205000 USD
CY2016Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1942000 USD
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-302000 USD
CY2015Q4 us-gaap Fair Value Concentration Of Risk Accounts Receivable
FairValueConcentrationOfRiskAccountsReceivable
0.76 USD
CY2016Q2 us-gaap Fair Value Concentration Of Risk Accounts Receivable
FairValueConcentrationOfRiskAccountsReceivable
0.78 USD
CY2016Q2 us-gaap Finite Lived Intangible Assets Amortization Expense After Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
1517000 USD
CY2016Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
141000 USD
CY2016Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
280000 USD
CY2016Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
280000 USD
CY2016Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
280000 USD
CY2016Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
280000 USD
CY2016Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
2778000 USD
CY2015Q2 us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
-6000 USD
us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
-10000 USD
CY2016Q2 us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
-1000 USD
us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
-11000 USD
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
35000 USD
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
0 USD
CY2015Q2 us-gaap Gross Profit
GrossProfit
6689000 USD
us-gaap Gross Profit
GrossProfit
11970000 USD
CY2016Q2 us-gaap Gross Profit
GrossProfit
5523000 USD
us-gaap Gross Profit
GrossProfit
13071000 USD
CY2016Q2 us-gaap Incentive From Lessor
IncentiveFromLessor
2000000 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-412000 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-2305000 USD
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-1458000 USD
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-711000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
157000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1099000 USD
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
1235000 USD
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
385000 USD
us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
-8000 USD
us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
0 USD
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
789000 USD
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-1888000 USD
CY2015Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
2917000 USD
CY2016Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
2778000 USD
CY2015Q2 us-gaap Interest Expense
InterestExpense
2000 USD
us-gaap Interest Expense
InterestExpense
4000 USD
CY2016Q2 us-gaap Interest Expense
InterestExpense
3000 USD
us-gaap Interest Expense
InterestExpense
6000 USD
CY2015Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
20000 USD
CY2016Q2 us-gaap Inventory Finished Goods
InventoryFinishedGoods
28000 USD
CY2015Q4 us-gaap Inventory Net
InventoryNet
1379000 USD
CY2016Q2 us-gaap Inventory Net
InventoryNet
2393000 USD
CY2015Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
1228000 USD
CY2016Q2 us-gaap Inventory Raw Materials
InventoryRawMaterials
2089000 USD
CY2015Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
131000 USD
CY2016Q2 us-gaap Inventory Work In Process
InventoryWorkInProcess
276000 USD
CY2015Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
9000 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
22000 USD
CY2016Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
2000 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
7000 USD
CY2015Q4 us-gaap Liabilities
Liabilities
12179000 USD
CY2016Q2 us-gaap Liabilities
Liabilities
12327000 USD
CY2015Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
34309000 USD
CY2016Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
29434000 USD
CY2015Q4 us-gaap Liabilities Current
LiabilitiesCurrent
12108000 USD
CY2016Q2 us-gaap Liabilities Current
LiabilitiesCurrent
11455000 USD
CY2016Q2 us-gaap Line Of Credit Facility Remaining Borrowing Capacity
LineOfCreditFacilityRemainingBorrowingCapacity
7200000 USD
CY2016Q2 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
2400000 USD
CY2015Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
71000 USD
CY2016Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
52000 USD
CY2016Q2 us-gaap Minimum Lease Payments Sale Leaseback Transactions Due In Rolling After Year Five
MinimumLeasePaymentsSaleLeasebackTransactionsDueInRollingAfterYearFive
4386000 USD
us-gaap Net Cash Provided By Used In Continuing Operations
NetCashProvidedByUsedInContinuingOperations
-10125000 USD
us-gaap Net Cash Provided By Used In Continuing Operations
NetCashProvidedByUsedInContinuingOperations
-4746000 USD
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
-14000 USD
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
2637000 USD
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-1520000 USD
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-981000 USD
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-8591000 USD
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-6402000 USD
CY2015Q2 us-gaap Net Income Loss
NetIncomeLoss
-2152000 USD
us-gaap Net Income Loss
NetIncomeLoss
-7014000 USD
CY2016Q2 us-gaap Net Income Loss
NetIncomeLoss
-3044000 USD
us-gaap Net Income Loss
NetIncomeLoss
-6694000 USD
CY2015Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-3806000 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-10258000 USD
CY2016Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-4900000 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-10354000 USD
CY2015Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
113000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-177000 USD
CY2016Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1940000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
282000 USD
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1 segment
CY2015Q2 us-gaap Operating Expenses
OperatingExpenses
8954000 USD
us-gaap Operating Expenses
OperatingExpenses
18807000 USD
CY2016Q2 us-gaap Operating Expenses
OperatingExpenses
10507000 USD
us-gaap Operating Expenses
OperatingExpenses
20047000 USD
CY2015Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-2265000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-6837000 USD
CY2016Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-4984000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-6976000 USD
CY2016Q2 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
25538000 USD
CY2016Q2 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
4386000 USD
CY2016Q2 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
4267000 USD
CY2016Q2 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
4590000 USD
CY2016Q2 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
4897000 USD
CY2016Q2 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
5275000 USD
CY2016Q2 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
2123000 USD
CY2015Q2 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
1300000 USD
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
2500000 USD
CY2016Q2 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
1200000 USD
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
2400000 USD
CY2015Q4 us-gaap Other Assets Current
OtherAssetsCurrent
464000 USD
CY2016Q2 us-gaap Other Assets Current
OtherAssetsCurrent
1046000 USD
CY2015Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
0 USD
CY2016Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
0 USD
CY2015Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
42000 USD
CY2016Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
39000 USD
us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
-35000 USD
CY2015Q2 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
1654000 USD
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
3244000 USD
CY2016Q2 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
1856000 USD
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
3660000 USD
us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
3000 USD
us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
352000 USD
us-gaap Proceeds From Secured Lines Of Credit
ProceedsFromSecuredLinesOfCredit
0 USD
us-gaap Proceeds From Secured Lines Of Credit
ProceedsFromSecuredLinesOfCredit
2400000 USD
CY2015Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
9687000 USD
CY2016Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
10677000 USD
CY2015Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4049000 USD
CY2016Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4351000 USD
CY2016Q2 us-gaap Purchase Obligation
PurchaseObligation
450000 USD
CY2016Q2 us-gaap Purchase Obligation Due In Fifth Year
PurchaseObligationDueInFifthYear
0 USD
CY2016Q2 us-gaap Purchase Obligation Due In Fourth Year
PurchaseObligationDueInFourthYear
0 USD
CY2016Q2 us-gaap Purchase Obligation Due In Next Twelve Months
PurchaseObligationDueInNextTwelveMonths
450000 USD
CY2016Q2 us-gaap Purchase Obligation Due In Second Year
PurchaseObligationDueInSecondYear
0 USD
CY2016Q2 us-gaap Purchase Obligation Due In Third Year
PurchaseObligationDueInThirdYear
0 USD
us-gaap Repayments Of Debt
RepaymentsOfDebt
17000 USD
us-gaap Repayments Of Debt
RepaymentsOfDebt
19000 USD
CY2015Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3369000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7746000 USD
CY2016Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4058000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7594000 USD
CY2015Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-324025000 USD
CY2016Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-330719000 USD
CY2015Q2 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
13590000 USD
us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
24439000 USD
CY2016Q2 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
12823000 USD
us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
26931000 USD
CY2015Q2 us-gaap Sales Revenue Net
SalesRevenueNet
13590000 USD
us-gaap Sales Revenue Net
SalesRevenueNet
24439000 USD
CY2016Q2 us-gaap Sales Revenue Net
SalesRevenueNet
12823000 USD
us-gaap Sales Revenue Net
SalesRevenueNet
26931000 USD
CY2015Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
5585000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
11061000 USD
CY2016Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
6449000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
12453000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
1614000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
1319000 USD
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
76827000 USD
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
150224000 USD
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
8439000 USD
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
5000000 USD
CY2016Q2 us-gaap Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
60992 shares
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
22130000 USD
CY2016Q2 us-gaap Stockholders Equity
StockholdersEquity
17107000 USD
us-gaap Straight Line Rent
StraightLineRent
0 USD
us-gaap Straight Line Rent
StraightLineRent
-260000 USD
CY2015Q4 us-gaap Treasury Stock Value
TreasuryStockValue
3150000 USD
CY2016Q2 us-gaap Treasury Stock Value
TreasuryStockValue
3150000 USD
CY2015Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
757000 USD
CY2016Q2 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
455000 USD
CY2015Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
23786000 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
23786000 shares
CY2016Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
22684000 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
22644000 shares
us-gaap Basis Of Accounting
BasisOfAccounting
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Basis of Presentation</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The condensed consolidated financial statements included herein have been prepared in accordance with the rules&#160;and regulations of the U.S. Securities and Exchange Commission (SEC).&#160; The preparation of condensed consolidated financial statements in conformity with generally accepted accounting principles in the United States of America (U.S. GAAP) requires management to make estimates, judgments, and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been omitted pursuant to such rules&#160;and regulations. The financial statements reflect, in the opinion of management, all adjustments (consisting only of normal, recurring adjustments) necessary to state fairly the financial position and results of operations as of and for the periods indicated.&#160; The results of operations for the </font><font style="font-family:inherit;font-size:10pt;">three and six</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, are not necessarily indicative of the results to be expected for the full year or for any other period.&#160; The </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> condensed consolidated balance sheet data was derived from the Company&#8217;s audited consolidated financial statements, but does not include all disclosures required by U.S. GAAP.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the notes thereto included in our Annual Report on Form&#160;10-K for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">, as filed with the SEC on March&#160;14, 2016 (Annual Report).</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The consolidated financial statements include the accounts of Vericel and its wholly-owned subsidiaries, Marrow Donation, LLC, located in San Diego, California, and Vericel Denmark ApS, in Kastrup, Demark (collectively, the Company).&#160; All inter-company transactions and accounts have been eliminated in consolidation.&#160; Aastrom Biosciences GmbH ceased operations in 2014 and Marrow Donation, LLC and Vericel Denmark ApS ceased operations in 2015.</font></div></div>
us-gaap Nature Of Operations
NatureOfOperations
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Organization</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vericel Corporation, a Michigan corporation, which was formerly known as Aastrom Biosciences,&#160;Inc. (the Company, Vericel, we, us or our), was incorporated in March&#160;1989 and began employee-based operations in 1991. On May&#160;30, 2014, Vericel completed the acquisition of certain assets and assumed certain liabilities of Sanofi, a French soci&#233;t&#233; anonyme (Sanofi), including all of the outstanding equity interests of Genzyme Biosurgery ApS (Genzyme Denmark or the Danish subsidiary) (now known as Vericel Denmark ApS), a wholly-owned subsidiary of Sanofi, and over </font><font style="font-family:inherit;font-size:10pt;">250</font><font style="font-family:inherit;font-size:10pt;"> patent applications of Sanofi and certain of its subsidiaries for purposes of acquiring the portion of the cell therapy and regenerative medicine business (the CTRM Business), which researches, develops, manufactures, markets and sells the Carticel</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">, MACI</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">,&#160;and Epicel</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#160;products. The Company is a fully integrated, commercial-stage biopharmaceutical company dedicated to the identification, development and commercialization of innovative therapies that enable the body to repair and regenerate damaged tissues and organs to restore normal structure and function. Vericel has marketed products as well as developmental stage product candidates and the Company&#8217;s goal is to become the leader in cell therapy and regenerative medicine by developing, manufacturing and marketing best-in-class therapies for patients with significant unmet medical needs.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company operates its business primarily in the U.S. in </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> reportable segment &#8212; the research, product development, manufacture and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Successful future operations are subject to several technical hurdles and risk factors, including satisfactory product development, timely initiation and completion of clinical trials, regulatory approval and market acceptance of the Company&#8217;s products.</font></div></div>

Files In Submission

Name View Source Status
0001628280-16-018710-index-headers.html Edgar Link pending
0001628280-16-018710-index.html Edgar Link pending
0001628280-16-018710.txt Edgar Link pending
0001628280-16-018710-xbrl.zip Edgar Link pending
astm-20160630.xml Edgar Link completed
astm-20160630.xsd Edgar Link pending
astm-20160630_cal.xml Edgar Link unprocessable
astm-20160630_def.xml Edgar Link unprocessable
astm-20160630_lab.xml Edgar Link unprocessable
astm-20160630_pre.xml Edgar Link unprocessable
ex101ventionagreement.htm Edgar Link pending
ex102dohmen-1stamendmentto.htm Edgar Link pending
ex103dohmen-2ndamendmentto.htm Edgar Link pending
ex104transitionservicesagr.htm Edgar Link pending
ex311q22016-ceocertificati.htm Edgar Link pending
ex312q22016cfocertification.htm Edgar Link pending
ex321q22016-ceosoxcertific.htm Edgar Link pending
ex322q22016-cfosoxcertific.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
vericel6301610q.htm Edgar Link pending